Ergoteles LLC Arcus Biosciences, Inc. Transaction History

Ergoteles LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $695,508 - $1.26 Million	35,305 New	35,305 $730,000
Q2 2022 Aug 12, 2022	SELL	$17.23 - $37.73 $688,614 - $1.51 Million	-39,966 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$28.92 - $41.83 $1.16 Million - $1.67 Million	39,966 New	39,966 $1.26 Million
Q4 2021 Feb 14, 2022	SELL	$31.38 - $48.47 $207,108 - $319,902	-6,600 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$26.93 - $37.68 $177,738 - $248,688	6,600 New	6,600 $230,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.